Log In
BCIQ
Print this Print this
 

entrectinib (formerly RXDX-101)

  Manage Alerts
Collapse Summary General Information
Company Nerviano Medical Sciences s.r.l.
DescriptionOral inhibitor of c-ros proto-oncogene 1 receptor tyrosine kinase (ROS1), neurotrophic tyrosine kinase receptor 1 (TrkA; NTRK1), TrkB (NTRK2), TrkC (NTRK3) and anaplastic lymphoma kinase (ALK)
Molecular Target c-ros proto-oncogene 1 receptor tyrosine kinase (ROS1) ; Neurotrophic tyrosine kinase receptor 1 (TrkA) (NTRK1)
Mechanism of ActionKinase inhibitor; Anaplastic lymphoma kinase (ALK) inhibitor
Therapeutic ModalitySmall molecule

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$112.0M

$6.0M

$105.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

07/06/2015

Undisclosed

0

0

11/06/2013

$112.0M

$6.0M

$105.0M

Get a free BioCentury trial today